ADC Therapeutics

NYSE: ADCT · SEC EDGAR filings

Results on file1
Average 24h move−55.84%across 1 result with a complete 24h price
1 resultADC Therapeutics
Met endpoint

ZYNLONTA

Phase 3 n=440 Relapsed Diffuse Large B-Cell Lymphoma

ADC Therapeutics ADCT

24h stock move −55.84%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.